Jazz Pharmaceuticals
(NASDAQ:JAZZ)
$120.42
-0.09[-0.07%]
At close: Mar 28
$120.42
0[0.00%]
After Hours: 4:02PM EDT
Consensus Rating1
Buy
Highest Price Target1
$230.00
Lowest Price Target1
$131.00
Consensus Price Target1
$184.70

Jazz Pharmaceuticals Stock (NASDAQ:JAZZ), Analyst Ratings, Price Targets, Predictions

Jazz Pharmaceuticals PLC has a consensus price target of $184.7, established from looking at the 67 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Cantor Fitzgerald, and Truist Securities on March 22, 2024, March 22, 2024, and March 20, 2024. With an average price target of $190 between JP Morgan, Cantor Fitzgerald, and Truist Securities, there's an implied 57.78% upside for Jazz Pharmaceuticals PLC from these 3 analyst ratings.

Analyst Rating Summary1

Analyst Ratings
Sep 23
1
Nov 23
3
1
Dec 23
1
Jan
2
Feb
4
Mar
8
1
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

JP Morgan
Cantor Fitzgerald
Truist Securities
Piper Sandler
Needham

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Jazz Pharmaceuticals

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/22/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4257.78%JP Morgan
Jessica Fye
$170 → $190MaintainsOverweightGet Alert
03/22/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4249.48%Cantor Fitzgerald
Charles Duncan
→ $180ReiteratesOverweight → OverweightGet Alert
03/20/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4266.09%Truist Securities
Joon Lee
→ $200ReiteratesBuy → BuyGet Alert
03/20/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4256.12%Piper Sandler
David Amsellem
$171 → $188ReiteratesOverweight → OverweightGet Alert
03/20/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4282.69%Needham
Ami Fadia
→ $220ReiteratesBuy → BuyGet Alert
03/15/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4291%Stifel
Annabel Samimy
$225 → $230MaintainsBuyGet Alert
03/14/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4266.09%HC Wainwright & Co.
Oren Livnat
$204 → $200MaintainsBuyGet Alert
03/01/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4291%Barclays
Balaji Prasad
$235 → $230MaintainsOverweightGet Alert
03/01/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.428.79%UBS
Ashwani Verma
$135 → $131MaintainsNeutralGet Alert
02/29/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4249.48%Cantor Fitzgerald
Charles Duncan
→ $180ReiteratesOverweight → OverweightGet Alert
02/29/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4261.93%RBC Capital
Gregory Renza
→ $195ReiteratesOutperform → OutperformGet Alert
02/29/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4241.17%JP Morgan
Jessica Fye
$180 → $170MaintainsOverweightGet Alert
02/29/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4282.69%Needham
Ami Fadia
$225 → $220MaintainsBuyGet Alert
01/29/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4295.15%Barclays
Balaji Prasad
$240 → $235MaintainsOverweightGet Alert
01/03/2024JAZZBuy Now
Jazz Pharmaceuticals
$120.4232.87%Baird
Joel Beatty
→ $160Initiates → OutperformGet Alert
12/04/2023JAZZBuy Now
Jazz Pharmaceuticals
$120.4266.09%Truist Securities
Joon Lee
→ $200ReiteratesBuy → BuyGet Alert
11/29/2023JAZZBuy Now
Jazz Pharmaceuticals
$120.4286.85%Needham
Ami Fadia
→ $225ReiteratesBuy → BuyGet Alert
11/27/2023JAZZBuy Now
Jazz Pharmaceuticals
$120.4212.11%UBS
Ashwani Verma
$170 → $135DowngradeBuy → NeutralGet Alert
11/09/2023JAZZBuy Now
Jazz Pharmaceuticals
$120.4258.61%RBC Capital
Gregory Renza
$200 → $191MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Jazz Pharmaceuticals (JAZZ)?

A

The latest price target for Jazz Pharmaceuticals (NASDAQ: JAZZ) was reported by JP Morgan on March 22, 2024. The analyst firm set a price target for $190.00 expecting JAZZ to rise to within 12 months (a possible 57.78% upside). 35 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Jazz Pharmaceuticals (JAZZ)?

A

The latest analyst rating for Jazz Pharmaceuticals (NASDAQ: JAZZ) was provided by JP Morgan, and Jazz Pharmaceuticals maintained their overweight rating.

Q

When was the last upgrade for Jazz Pharmaceuticals (JAZZ)?

A

The last upgrade for Jazz Pharmaceuticals PLC happened on December 9, 2022 when Goldman Sachs raised their price target to $190. Goldman Sachs previously had a neutral for Jazz Pharmaceuticals PLC.

Q

When was the last downgrade for Jazz Pharmaceuticals (JAZZ)?

A

The last downgrade for Jazz Pharmaceuticals PLC happened on November 27, 2023 when UBS changed their price target from $170 to $135 for Jazz Pharmaceuticals PLC.

Q

When is the next analyst rating going to be posted or updated for Jazz Pharmaceuticals (JAZZ)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on March 22, 2024 so you should expect the next rating to be made available sometime around March 22, 2025.

Q

Is the Analyst Rating Jazz Pharmaceuticals (JAZZ) correct?

A

While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $170.00 to $190.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $120.42, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch